Amedisys (NASDAQ:AMED – Get Rating) had its price target dropped by investment analysts at SVB Leerink from $116.00 to $96.00 in a research report issued on Tuesday, Benzinga reports. The brokerage presently has a “market perform” rating on the health services provider’s stock. SVB Leerink’s price target would indicate a potential downside of 0.53% from the stock’s previous close.
AMED has been the topic of a number of other research reports. Royal Bank of Canada cut their price target on shares of Amedisys from $165.00 to $139.00 and set an “outperform” rating on the stock in a report on Monday. Truist Financial decreased their target price on shares of Amedisys from $140.00 to $130.00 and set a “buy” rating for the company in a research note on Friday. Benchmark dropped their price target on shares of Amedisys from $165.00 to $135.00 and set a “buy” rating on the stock in a research note on Monday, October 3rd. Stephens lifted their price objective on Amedisys from $105.00 to $122.00 and gave the company an “equal weight” rating in a research report on Tuesday. Finally, Cowen lowered their target price on Amedisys to $125.00 in a research note on Tuesday, August 9th. Two analysts have rated the stock with a sell rating, four have assigned a hold rating and ten have given a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $142.06.
Amedisys Price Performance
Shares of NASDAQ AMED traded down $1.08 during midday trading on Tuesday, reaching $96.51. The company’s stock had a trading volume of 17,145 shares, compared to its average volume of 529,278. Amedisys has a one year low of $86.89 and a one year high of $188.88. The company has a market cap of $3.14 billion, a price-to-earnings ratio of 26.01, a price-to-earnings-growth ratio of 3.12 and a beta of 1.01. The company has a 50 day moving average price of $108.24 and a 200 day moving average price of $117.13. The company has a current ratio of 1.06, a quick ratio of 1.06 and a debt-to-equity ratio of 0.41.
Amedisys (NASDAQ:AMED – Get Rating) last announced its quarterly earnings data on Thursday, October 27th. The health services provider reported $1.15 EPS for the quarter, missing analysts’ consensus estimates of $1.22 by ($0.07). Amedisys had a net margin of 5.45% and a return on equity of 16.00%. The company had revenue of $557.99 million for the quarter, compared to analyst estimates of $579.30 million. During the same quarter last year, the company posted $1.53 EPS. Amedisys’s revenue was up .8% on a year-over-year basis. On average, equities research analysts expect that Amedisys will post 4.99 EPS for the current year.
Hedge Funds Weigh In On Amedisys
Several large investors have recently made changes to their positions in the business. Allworth Financial LP bought a new position in Amedisys in the 1st quarter worth approximately $38,000. First Horizon Advisors Inc. raised its stake in shares of Amedisys by 862.5% in the second quarter. First Horizon Advisors Inc. now owns 385 shares of the health services provider’s stock valued at $40,000 after purchasing an additional 345 shares in the last quarter. Neo Ivy Capital Management bought a new position in Amedisys in the second quarter worth $44,000. Northwestern Mutual Wealth Management Co. bought a new stake in Amedisys in the 1st quarter valued at $46,000. Finally, Covestor Ltd raised its stake in shares of Amedisys by 88.9% in the 1st quarter. Covestor Ltd now owns 323 shares of the health services provider’s stock valued at $56,000 after buying an additional 152 shares in the last quarter. Institutional investors and hedge funds own 93.36% of the company’s stock.
About Amedisys
Amedisys, Inc engages in the provision of healthcare services. It operates through the following business segments: Home Health, Hospice, and Personal Care. The Home Health segment delivers services in the homes of individuals who may be recovering from an illness, injury, or surgery. The Hospice segment provides care that is designed to provide comfort and support for those who are facing a terminal illness.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Amedisys, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Amedisys wasn’t on the list.
While Amedisys currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better buys.
Read More: SVB Leerink Lowers Amedisys (NASDAQ:AMED) Price Target to $96.00